Trial Profile
GSK1550188, A Randomised, Single-blind, Placebo Controlled, Dose Ascending, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Dec 2023
Price :
$35
*
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 29 Jun 2011 New trial record